Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01313676
Other study ID # 113782
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date January 25, 2011
Est. completion date July 15, 2015

Study information

Verified date August 2018
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.


Description:

Despite a potential link between the pathogenetic mechanisms involved in Chronic Obstructive Pulmonary Disease (COPD) and atherosclerotic cardiovascular disease, there are no currently approved therapies for patients with COPD that have clearly shown an additional beneficial effect in patients with cardiovascular comorbidities. The TOwards a Revolution in COPD Health (TORCH) study assessed the impact of the inhaled corticosteroid (ICS) fluticasone propionate (FP) in combination with the long-acting beta agonist (LABA), salmeterol (SAL), in reducing all-cause mortality. TORCH demonstrated a 17.5% reduction on all-cause mortality with salmeterol-fluticasone propionate combination (SFC) compared with placebo (HR=0.825, 95% CI (0.681, 1.002), p=0.052) in the entire COPD population with disease severity form moderate to very severe. A post hoc analysis of the data restricted to those subjects with an forced expiratory volume in 1 second (FEV1) >=50% predicted with an apparent history of cardiovascular co-morbidities (defined as use at baseline of beta-blockers, angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB), HMG CoA reductase inhibitors (i.e. statins) or a prior MI recorded at baseline) demonstrated a 49% reduction in the risk of dying within 96 weeks for the comparison of SFC with placebo. These post hoc data suggest the possibility of an ICS/LABA combination product to be of substantial benefit in COPD subjects with less severe airflow obstruction yet with increased cardiovascular risk.

The mechanism by which SFC appears to be associated with a greater reduction in mortality in these less severe COPD subjects with concomitant cardiovascular comorbidities is speculative at present, but could potentially in part be related to a lessening of the degree of inflammation in the systemic circulation, potential plaque stabilization and/or amelioration of arterial stiffness.

ICS/LABA combinations that are currently available require twice daily administration. A once daily ICS/LABA combination has the potential to improve patient compliance and as a result, overall disease management.

The purpose of this study is to prospectively evaluate the effect of the once daily ICS/LABA combination Fluticasone Furoate (FF)/Vilanterol (VI) on survival in subjects with moderate COPD (>=50 and =<70 % predicted FEV1 ) and a history of, or at increased risk for cardiovascular disease.


Recruitment information / eligibility

Status Completed
Enrollment 16568
Est. completion date July 15, 2015
Est. primary completion date July 15, 2015
Accepts healthy volunteers No
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria:

- Type of subject: outpatient.

- Informed consent: Subjects must give their signed and dated written informed consent to participate.

- Gender: Male or female. Female subjects must be post-menopausal or using a highly effective method for avoidance of pregnancy. The decision to include or exclude women of childbearing potential may be made at the discretion of the investigator in accordance with local practice in relation to adequate contraception.

- Age: >=40 and <=80 years of age at Screening (Visit 1).

- Tobacco use: Subjects with a current or prior history of >=10 pack-years of cigarette smoking at screening (Visit 1). Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1.

- Airflow Obstruction:

Subjects with a measured post-albuterol/salbutamol forced expiratory volume in 1 second (FEV1)/(forced vital capacity)FVC ratio of <=0.70 at Screening (Visit 1).

Subjects with a measured post-albuterol/salbutamol FEV1 >=50 and <=70% of predicted normal values calculated using NHANES III reference equations [Hankinson, 1999; Hankinson, 2010] at Screening (Visit 1).

Post-bronchodilator spirometry will be performed approximately 15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via a metered dose inhaler (MDI )with a valved-holding chamber. The FEV1/FVC ratio and FEV1 percent predicted values will be calculated.

- Symptoms of COPD: Subjects must score 2 or higher on the modified Medical Research Council Dyspnea scale (Visit 1)

- Cardiovascular disease:

For patients >= 40 years of age: any one of the following:

Established (i.e. by clinical signs or imaging studies) coronary artery disease (CAD) Established (i.e. by clinical signs or imaging studies) peripheral vascular disease (PVD) Previous stroke Previous MI Diabetes mellitus with target organ disease OR

For patients >=60 years of age: any 2 of the following:

Being treated for hypercholesterolemia Being treated for hypertension Being treated for diabetes mellitus Being treated for peripheral vascular disease

Exclusion Criteria:

- Pregnancy: Women who are pregnant or lactating.

- Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they also have a current diagnosis of COPD).

- alpha 1-antitrypsin deficiency: Subjects with known alpha-1 antitrypsin deficiency as the underlying cause of COPD.

- Other respiratory disorders: Subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases.

- Lung resection or transplantation: Subjects with lung volume reduction surgery within the 12 months prior to Screening or having had a lung transplant.

- A moderate/severe COPD exacerbation that has not resolved at least 14 days prior to Visit 1 and at least 30 days following the last dose of oral corticosteroids (if applicable).

- Current severe heart failure (New York Heart Association class IV). Subjects will also be excluded if they have a known ejection fraction of <30% or if they have an implantable cardioverter defibrillator (ICD).

- Other diseases/abnormalities: Any life-threatening condition with life expectancy <3 years, other than vascular disease or COPD, that might prevent the subject from completing the study.

- End stage chronic renal disease: Subjects will be excluded if on renal replacement therapy (hemodialysis or peritoneal).

- Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medications (e.g. beta-agonists, corticosteroid) or components of the inhalation powder (e.g. lactose, magnesium stearate). In addition, patients with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates the subject's participation will also be excluded.

- Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years.

- Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use (i.e. <=12 hours per day) is not exclusionary.

- Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study or the potential compliance to study procedures.

- Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study.

- Additional medication: Use of the following medications within the following time intervals prior to Visit 1 or during the study (unless otherwise specified):

Medication No use within the following time intervals prior to Screening or thereafter at any time during the study (unless otherwise specified) Inhaled Long acting beta-agonists (LABA) 48 hours ICS/LABA combination products 48 hours Inhaled corticosteroids 48 hours Tiotropium 1 week Systemic, Oral, parenteral, intra-articular corticosteroids 30 days (oral and systemic corticosteroids may be used to treat COPD exacerbations during the study) Cytochrome P450 3A4 strong inhibitors including but not limited to antiretrovirals (protease inhibitors) (e.g.Indinavir, Nelfinavir, Ritonavir, Saquinavir); Imidazole and Triazole anti-fungals (e.g. Ketaconazole, Itraconazole); Clarithromycin, Telithromycin, Amiodarone, and Nefazodone 6 weeks Grapefruit is allowed up to Visit 1, then limited to no more than one glass of grapefruit juice (250 mL/ 8 ounces) or one grapefruit per day Any other investigational drug 30 days or 5 half lives whichever is longer.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
fluticasone furoate/vilanterol
100/25mcg given once daily via novel dry powder inhaler
fluticasone furoate
100mcg given once daily via novel dry powder inhaler
vilanterol
25mcg given once daily via novel dry powder inhaler
Other:
Placebo
placebo comparator once daily via novel dry powder inhaler

Locations

Country Name City State
Argentina GSK Investigational Site Adrogue Buenos Aires
Argentina GSK Investigational Site Bahia Blanca Buenos Aires
Argentina GSK Investigational Site Buenos Aires
Argentina GSK Investigational Site Buenos Aires
Argentina GSK Investigational Site Buenos Aires
Argentina GSK Investigational Site Buenos Aires
Argentina GSK Investigational Site Buenos Aires
Argentina GSK Investigational Site Buenos Aires
Argentina GSK Investigational Site Buenos Aires
Argentina GSK Investigational Site Buenos Aires
Argentina GSK Investigational Site Cipoletti, Rio Negro Río Negro
Argentina GSK Investigational Site Ciudad Autnónoma de Buenos Aires Buenos Aires
Argentina GSK Investigational Site Ciudad Autonoma de Buenos Aires Buenos Aires
Argentina GSK Investigational Site Ciudad Autonoma de Buenos Aires Buenos Aires
Argentina GSK Investigational Site Ciudad Autonoma de Buenos Aires Buenos Aires
Argentina GSK Investigational Site Ciudad Autonoma de Buenos Aires
Argentina GSK Investigational Site Ciudad Autónoma de Buenos Aires
Argentina GSK Investigational Site Concepcion del Uruguay Entre Ríos
Argentina GSK Investigational Site Cordoba Córdova
Argentina GSK Investigational Site Cordoba Córdova
Argentina GSK Investigational Site Cordoba
Argentina GSK Investigational Site Cordoba
Argentina GSK Investigational Site Cordoba
Argentina GSK Investigational Site Cordoba
Argentina GSK Investigational Site Cordoba
Argentina GSK Investigational Site Cordoba
Argentina GSK Investigational Site Coronel Suarez
Argentina GSK Investigational Site Corrientes
Argentina GSK Investigational Site Derqui, Pilar Buenos Aires
Argentina GSK Investigational Site Florencio Varela Buenos Aires
Argentina GSK Investigational Site Florencio Varela
Argentina GSK Investigational Site Formosa
Argentina GSK Investigational Site Godoy Cruz Mendoza
Argentina GSK Investigational Site Jujuy
Argentina GSK Investigational Site La Plata Buenos Aires
Argentina GSK Investigational Site La Plata Buenos Aires
Argentina GSK Investigational Site Lanús
Argentina GSK Investigational Site Mar del Plata
Argentina GSK Investigational Site Mar del Plata Buenos Aires
Argentina GSK Investigational Site Mendoza
Argentina GSK Investigational Site Mendoza
Argentina GSK Investigational Site Mendoza
Argentina GSK Investigational Site Monte Grande
Argentina GSK Investigational Site Nueve de Julio Buenos Aires
Argentina GSK Investigational Site Olivos Buenos Aires
Argentina GSK Investigational Site Parana Entre Ríos
Argentina GSK Investigational Site Pergamino Buenos Aires
Argentina GSK Investigational Site Quilmes Buenos Aires
Argentina GSK Investigational Site Quilmes Buenos Aires
Argentina GSK Investigational Site Rosario Santa Fe
Argentina GSK Investigational Site Rosario Santa Fe
Argentina GSK Investigational Site Rosario Santa Fe
Argentina GSK Investigational Site Rosario Santa Fe
Argentina GSK Investigational Site Rosario Santa Fe
Argentina GSK Investigational Site Rosario
Argentina GSK Investigational Site Rosario
Argentina GSK Investigational Site Salta
Argentina GSK Investigational Site Salta
Argentina GSK Investigational Site San Isidro Buenos Aires
Argentina GSK Investigational Site San Luis
Argentina GSK Investigational Site San Martin Buenos Aires
Argentina GSK Investigational Site San Miguel de Tucuman
Argentina GSK Investigational Site San Miguel de Tucumán
Argentina GSK Investigational Site San Nicolas Buenos Aires
Argentina GSK Investigational Site San Nicolas Buenos Aires
Argentina GSK Investigational Site Santa Fe
Argentina GSK Investigational Site Santa Fe
Argentina GSK Investigational Site Santiago del Estero
Argentina GSK Investigational Site Tucuman Tucumán
Argentina GSK Investigational Site Vicente López Buenos Aires
Australia GSK Investigational Site Bedford Park South Australia
Australia GSK Investigational Site Cairns Queensland
Australia GSK Investigational Site Daw Park South Australia
Australia GSK Investigational Site Footscray Victoria
Australia GSK Investigational Site Geelong Victoria
Australia GSK Investigational Site Glen Osmond
Australia GSK Investigational Site Melbourne Victoria
Australia GSK Investigational Site Redcliffe Queensland
Austria GSK Investigational Site Feldbach
Austria GSK Investigational Site Feldkirch
Austria GSK Investigational Site Grieskirchen
Austria GSK Investigational Site Innsbruck
Austria GSK Investigational Site Linz
Austria GSK Investigational Site Salzburg
Austria GSK Investigational Site Salzburg
Austria GSK Investigational Site Spittal/Drau
Austria GSK Investigational Site Thalheim bei Wels
Austria GSK Investigational Site Vienna
Austria GSK Investigational Site Wels
Austria GSK Investigational Site Zwettl
Belarus GSK Investigational Site Brest
Belarus GSK Investigational Site Gomel
Belarus GSK Investigational Site Grodno
Belarus GSK Investigational Site Minsk
Belarus GSK Investigational Site Minsk
Belarus GSK Investigational Site Minsk
Belarus GSK Investigational Site Vitebsk
Belgium GSK Investigational Site Diest
Belgium GSK Investigational Site Erpent
Belgium GSK Investigational Site Gilly
Belgium GSK Investigational Site Mons
Belgium GSK Investigational Site Namur
Bosnia and Herzegovina GSK Investigational Site Banja Luka
Bosnia and Herzegovina GSK Investigational Site Banjaluka
Bosnia and Herzegovina GSK Investigational Site Bihac
Bosnia and Herzegovina GSK Investigational Site Bihac
Bosnia and Herzegovina GSK Investigational Site Bijeljina
Bosnia and Herzegovina GSK Investigational Site Brcko
Bosnia and Herzegovina GSK Investigational Site Foca
Bosnia and Herzegovina GSK Investigational Site Gracanica
Bosnia and Herzegovina GSK Investigational Site Gradiska
Bosnia and Herzegovina GSK Investigational Site Istocno Sarajevo
Bosnia and Herzegovina GSK Investigational Site Konjic
Bosnia and Herzegovina GSK Investigational Site Mostar
Bosnia and Herzegovina GSK Investigational Site Novi Travnik
Bosnia and Herzegovina GSK Investigational Site Pale
Bosnia and Herzegovina GSK Investigational Site Sarajevo
Bosnia and Herzegovina GSK Investigational Site Sarajevo
Bosnia and Herzegovina GSK Investigational Site Srebrenik
Bosnia and Herzegovina GSK Investigational Site Tesanj
Bosnia and Herzegovina GSK Investigational Site Teslic
Bosnia and Herzegovina GSK Investigational Site Travnik
Bosnia and Herzegovina GSK Investigational Site Trebinje
Bosnia and Herzegovina GSK Investigational Site Tuzla
Bosnia and Herzegovina GSK Investigational Site Visegrad
Bosnia and Herzegovina GSK Investigational Site Zenica
Bulgaria GSK Investigational Site Blagoevgrad
Bulgaria GSK Investigational Site Dimitrovgrad
Bulgaria GSK Investigational Site Gabrovo
Bulgaria GSK Investigational Site Kozlodui
Bulgaria GSK Investigational Site Lovech
Bulgaria GSK Investigational Site Pazardjik
Bulgaria GSK Investigational Site Petrich
Bulgaria GSK Investigational Site Pleven
Bulgaria GSK Investigational Site Plovdiv
Bulgaria GSK Investigational Site Razgrad
Bulgaria GSK Investigational Site Rousse
Bulgaria GSK Investigational Site Sevlievo
Bulgaria GSK Investigational Site Sliven
Bulgaria GSK Investigational Site Sofia
Bulgaria GSK Investigational Site Sofia
Bulgaria GSK Investigational Site Sofia
Bulgaria GSK Investigational Site Sofia
Bulgaria GSK Investigational Site Sofia
Bulgaria GSK Investigational Site Sofia
Bulgaria GSK Investigational Site Sofia
Bulgaria GSK Investigational Site Sofia
Bulgaria GSK Investigational Site Sofia
Bulgaria GSK Investigational Site Sofia
Bulgaria GSK Investigational Site Stara Zagora
Bulgaria GSK Investigational Site Stara Zagora
Bulgaria GSK Investigational Site Troyan
Bulgaria GSK Investigational Site Varna
Bulgaria GSK Investigational Site Veliko Tarnovo
Bulgaria GSK Investigational Site Vidin
Canada GSK Investigational Site Bolton Ontario
Canada GSK Investigational Site Burlington Ontario
Canada GSK Investigational Site Edmonton Alberta
Canada GSK Investigational Site Edmonton Alberta
Canada GSK Investigational Site Grimsby Ontario
Canada GSK Investigational Site Kamloops British Columbia
Canada GSK Investigational Site London Ontario
Canada GSK Investigational Site Mirabel Quebec
Canada GSK Investigational Site Mississauga Ontario
Canada GSK Investigational Site Mississauga Ontario
Canada GSK Investigational Site Montreal Quebec
Canada GSK Investigational Site Newmarket Ontario
Canada GSK Investigational Site Orleans Ontario
Canada GSK Investigational Site Penticton British Columbia
Canada GSK Investigational Site Quebec
Canada GSK Investigational Site Sainte Jerome Quebec
Canada GSK Investigational Site Sarnia Ontario
Canada GSK Investigational Site Toronto Ontario
Canada GSK Investigational Site Vancouver British Columbia
Canada GSK Investigational Site West Vancouver British Columbia
Canada GSK Investigational Site Windsor Ontario
Canada GSK Investigational Site Winnipeg Manitoba
Chile GSK Investigational Site Santiago Región Metro De Santiago
Chile GSK Investigational Site Santiago Región Metro De Santiago
Chile GSK Investigational Site Santiago Región Metro De Santiago
Chile GSK Investigational Site Temuco Región De La Araucania
Chile GSK Investigational Site Temuco Región De La Araucania
Chile GSK Investigational Site Viña del Mar Valparaíso
China GSK Investigational Site Baotou Inner Mongolia
China GSK Investigational Site Baotou
China GSK Investigational Site Beijing
China GSK Investigational Site Beijing
China GSK Investigational Site Beijing
China GSK Investigational Site Beijing
China GSK Investigational Site Beijing
China GSK Investigational Site Bengbu
China GSK Investigational Site Changchun
China GSK Investigational Site Chengdu
China GSK Investigational Site Chengdu Sichuan
China GSK Investigational Site Chongqing
China GSK Investigational Site Chongqing
China GSK Investigational Site Chongqing
China GSK Investigational Site Fu Zhou
China GSK Investigational Site Fuzhou
China GSK Investigational Site Guangxi
China GSK Investigational Site Guangzhou
China GSK Investigational Site Guangzhou Guangdong
China GSK Investigational Site Guangzhou Guangdong
China GSK Investigational Site Guangzhou Guangdong
China GSK Investigational Site Haikou Hainan
China GSK Investigational Site Haikou Hainan
China GSK Investigational Site Hangzhou
China GSK Investigational Site Hefei
China GSK Investigational Site Hohhot Hainan
China GSK Investigational Site Huai'an
China GSK Investigational Site Jiangyin
China GSK Investigational Site Jinan Shandong
China GSK Investigational Site Luzhou
China GSK Investigational Site Nanchang
China GSK Investigational Site Nanjing
China GSK Investigational Site Nanning Guangxi
China GSK Investigational Site Shanghai
China GSK Investigational Site Shanghai
China GSK Investigational Site Shanghai
China GSK Investigational Site Shanghai
China GSK Investigational Site ShangHai
China GSK Investigational Site Shanghai
China GSK Investigational Site Shanghai
China GSK Investigational Site Shenyang Liaoning
China GSK Investigational Site Shenzhen Guangdong
China GSK Investigational Site Shijiazhuang Hebei
China GSK Investigational Site Taiyuan Shanxi
China GSK Investigational Site Tianjin
China GSK Investigational Site Wuhan Hubei
China GSK Investigational Site Wuxi
China GSK Investigational Site Xian Shaanxi
China GSK Investigational Site Yinchuan Ningxia
China GSK Investigational Site Zhanjiang Guangdong
Colombia GSK Investigational Site Barranquilla
Colombia GSK Investigational Site Bogota
Colombia GSK Investigational Site Bogota
Colombia GSK Investigational Site Bogotá
Colombia GSK Investigational Site Bogotá
Colombia GSK Investigational Site Cali
Colombia GSK Investigational Site Medellin
Colombia GSK Investigational Site Medellin
Colombia GSK Investigational Site Zipaquira
Croatia GSK Investigational Site Cakovec
Croatia GSK Investigational Site Draganic
Croatia GSK Investigational Site Hrasce Turopoljsko
Croatia GSK Investigational Site Hreljin
Croatia GSK Investigational Site Ivankovo
Croatia GSK Investigational Site Karlovac
Croatia GSK Investigational Site Klenovnik
Croatia GSK Investigational Site Krapina
Croatia GSK Investigational Site Kutina
Croatia GSK Investigational Site Novi Marof
Croatia GSK Investigational Site Osijek
Croatia GSK Investigational Site Retkovci
Croatia GSK Investigational Site Rijeka
Croatia GSK Investigational Site Samobor
Croatia GSK Investigational Site Senj
Croatia GSK Investigational Site Sibenik
Croatia GSK Investigational Site Sisak
Croatia GSK Investigational Site Split
Croatia GSK Investigational Site Strmec Samoborski
Croatia GSK Investigational Site Stubicke toplice
Croatia GSK Investigational Site Sukosan
Croatia GSK Investigational Site Varazdin
Croatia GSK Investigational Site Zabok
Croatia GSK Investigational Site Zadar
Croatia GSK Investigational Site Zagreb
Czechia GSK Investigational Site Benesov
Czechia GSK Investigational Site Beroun
Czechia GSK Investigational Site Brno
Czechia GSK Investigational Site Havlickuv brod
Czechia GSK Investigational Site Hlucin
Czechia GSK Investigational Site Holesov
Czechia GSK Investigational Site Jaromer
Czechia GSK Investigational Site Jindrichuv Hradec
Czechia GSK Investigational Site Kolin
Czechia GSK Investigational Site Kralupy nad Vltavou
Czechia GSK Investigational Site Kromeriz
Czechia GSK Investigational Site Liberec
Czechia GSK Investigational Site Melnik
Czechia GSK Investigational Site Moravsky Krumlov
Czechia GSK Investigational Site Neratovice
Czechia GSK Investigational Site Novy Jicin
Czechia GSK Investigational Site Ostrava
Czechia GSK Investigational Site Ostrava - Belsky les
Czechia GSK Investigational Site Ostrava - Poruba
Czechia GSK Investigational Site Plzen
Czechia GSK Investigational Site Plzen
Czechia GSK Investigational Site Praha 1
Czechia GSK Investigational Site Praha 13
Czechia GSK Investigational Site Praha 17
Czechia GSK Investigational Site Praha 3
Czechia GSK Investigational Site Praha 4
Czechia GSK Investigational Site Praha 4
Czechia GSK Investigational Site Praha 5
Czechia GSK Investigational Site Praha 6
Czechia GSK Investigational Site Rokycany
Czechia GSK Investigational Site Rudna
Czechia GSK Investigational Site Strakonice
Czechia GSK Investigational Site Strakonice
Czechia GSK Investigational Site Svitavy
Czechia GSK Investigational Site Tremosna
Czechia GSK Investigational Site Usti Nad Labem - Klise
Czechia GSK Investigational Site Zatec
France GSK Investigational Site Ferolles Attilly
France GSK Investigational Site Paris Cedex 04
France GSK Investigational Site Strasbourg Cedex
France GSK Investigational Site Tarbes
France GSK Investigational Site Toulouse cedex 9
Georgia GSK Investigational Site Batumi
Georgia GSK Investigational Site Gurjaani
Georgia GSK Investigational Site Kutaisi
Georgia GSK Investigational Site Kvemo Kartli
Georgia GSK Investigational Site Tbilisi
Georgia GSK Investigational Site Tbilisi
Georgia GSK Investigational Site Tbilisi
Georgia GSK Investigational Site Tbilisi
Georgia GSK Investigational Site Tbilisi
Georgia GSK Investigational Site Tbilisi
Georgia GSK Investigational Site Tbilisi
Georgia GSK Investigational Site Tbilisi
Georgia GSK Investigational Site Tbilisi
Georgia GSK Investigational Site Tbilisi
Georgia GSK Investigational Site Tbilisi
Germany GSK Investigational Site Aschaffenburg Bayern
Germany GSK Investigational Site Augsburg Bayern
Germany GSK Investigational Site Augsburg Bayern
Germany GSK Investigational Site Bad Woerrishofen Bayern
Germany GSK Investigational Site Bensheim Hessen
Germany GSK Investigational Site Bergisch Gladbach Nordrhein-Westfalen
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Bochum Nordrhein-Westfalen
Germany GSK Investigational Site Bonn Nordrhein-Westfalen
Germany GSK Investigational Site Bonn Nordrhein-Westfalen
Germany GSK Investigational Site Bruchsal Baden-Wuerttemberg
Germany GSK Investigational Site Cottbus Brandenburg
Germany GSK Investigational Site Darmstadt Hessen
Germany GSK Investigational Site Deggingen Baden-Wuerttemberg
Germany GSK Investigational Site Dortmund Nordrhein-Westfalen
Germany GSK Investigational Site Dresden Sachsen
Germany GSK Investigational Site Dresden Sachsen
Germany GSK Investigational Site Dueren Nordrhein-Westfalen
Germany GSK Investigational Site Essen Nordrhein-Westfalen
Germany GSK Investigational Site Essen Nordrhein-Westfalen
Germany GSK Investigational Site Ettlingen Baden-Wuerttemberg
Germany GSK Investigational Site Feldkirchen Bayern
Germany GSK Investigational Site Foehren Rheinland-Pfalz
Germany GSK Investigational Site Frankfurt Baden-Wuerttemberg
Germany GSK Investigational Site Fuerth Bayern
Germany GSK Investigational Site Gauting Bayern
Germany GSK Investigational Site Gelsenkirchen Nordrhein-Westfalen
Germany GSK Investigational Site Goerlitz Sachsen
Germany GSK Investigational Site Goettingen Niedersachsen
Germany GSK Investigational Site Hagen Nordrhein-Westfalen
Germany GSK Investigational Site Hagen Nordrhein-Westfalen
Germany GSK Investigational Site Hamburg
Germany GSK Investigational Site Hamburg
Germany GSK Investigational Site Hannover Niedersachsen
Germany GSK Investigational Site Harsewinkel Nordrhein-Westfalen
Germany GSK Investigational Site Hoechstadt Bayern
Germany GSK Investigational Site Ingelheim Rheinland-Pfalz
Germany GSK Investigational Site Jena Thueringen
Germany GSK Investigational Site Karlsruhe Baden-Wuerttemberg
Germany GSK Investigational Site Kassel Hessen
Germany GSK Investigational Site Koeln Nordrhein-Westfalen
Germany GSK Investigational Site Landsberg Bayern
Germany GSK Investigational Site Leipzg Sachsen
Germany GSK Investigational Site Leipzig Sachsen
Germany GSK Investigational Site Leipzig Sachsen
Germany GSK Investigational Site Leipzig Sachsen
Germany GSK Investigational Site Leipzig Sachsen
Germany GSK Investigational Site Magdeburg Sachsen-Anhalt
Germany GSK Investigational Site Mainz Rheinland-Pfalz
Germany GSK Investigational Site Marburg Hessen
Germany GSK Investigational Site Muenchen Bayern
Germany GSK Investigational Site München
Germany GSK Investigational Site Neuss Nordrhein-Westfalen
Germany GSK Investigational Site Neuwied Rheinland-Pfalz
Germany GSK Investigational Site Papenburg Niedersachsen
Germany GSK Investigational Site Potsdam Brandenburg
Germany GSK Investigational Site Reinfeld Schleswig-Holstein
Germany GSK Investigational Site Rhaunen Rheinland-Pfalz
Germany GSK Investigational Site Riesa Sachsen
Germany GSK Investigational Site Ruedersdorf Brandenburg
Germany GSK Investigational Site Schleswig Schleswig-Holstein
Germany GSK Investigational Site Solingen Nordrhein-Westfalen
Germany GSK Investigational Site Stuhr Niedersachsen
Germany GSK Investigational Site Vilshofen Bayern
Germany GSK Investigational Site Wardenburg Niedersachsen
Germany GSK Investigational Site Weissenhorn Bayern
Germany GSK Investigational Site Zerbst Sachsen-Anhalt
Greece GSK Investigational Site Athens
Greece GSK Investigational Site Athens
Greece GSK Investigational Site Thessaloniki
Hungary GSK Investigational Site Balassagyarmat
Hungary GSK Investigational Site Budapest
Hungary GSK Investigational Site Budapest
Hungary GSK Investigational Site Budapest
Hungary GSK Investigational Site Budapest
Hungary GSK Investigational Site Budapest
Hungary GSK Investigational Site Budapest
Hungary GSK Investigational Site Budapest
Hungary GSK Investigational Site Budapest
Hungary GSK Investigational Site Debrecen
Hungary GSK Investigational Site Debrecen
Hungary GSK Investigational Site Gyula
Hungary GSK Investigational Site Kaposvár
Hungary GSK Investigational Site Komarom
Hungary GSK Investigational Site Komló
Hungary GSK Investigational Site Mosonmagyaróvár
Hungary GSK Investigational Site Nagykanizsa
Hungary GSK Investigational Site Nyiregyhaza
Hungary GSK Investigational Site Pécs
Hungary GSK Investigational Site Sopron
Hungary GSK Investigational Site Szigetszentmiklos
Hungary GSK Investigational Site Szikszó
Hungary GSK Investigational Site Szombathely
Hungary GSK Investigational Site Tatabanya
Hungary GSK Investigational Site Vasarosnameny
Hungary GSK Investigational Site Zalaegerszeg
India GSK Investigational Site Ahmedabad
India GSK Investigational Site Ahmedabad
India GSK Investigational Site Alappuzha
India GSK Investigational Site Angamaly
India GSK Investigational Site Aurangabad
India GSK Investigational Site Bangalore
India GSK Investigational Site Bangalore
India GSK Investigational Site Bangalore
India GSK Investigational Site Bangalore
India GSK Investigational Site Chennai
India GSK Investigational Site Chennai
India GSK Investigational Site Guntur
India GSK Investigational Site Hyderabad
India GSK Investigational Site Hyderabad
India GSK Investigational Site Hyderabad
India GSK Investigational Site Jaipur
India GSK Investigational Site Jaipur
India GSK Investigational Site Lucknow
India GSK Investigational Site Mysore
India GSK Investigational Site Mysore
India GSK Investigational Site Nagpur
India GSK Investigational Site Nagpur
India GSK Investigational Site Nashik
India GSK Investigational Site Nasik
India GSK Investigational Site Pune
India GSK Investigational Site Pune
India GSK Investigational Site Trisshur
India GSK Investigational Site Trivandrum
India GSK Investigational Site Varanasi
India GSK Investigational Site Varanasi
India GSK Investigational Site Vijayawada
Indonesia GSK Investigational Site Banda Aceh
Indonesia GSK Investigational Site Banjarmasin
Indonesia GSK Investigational Site Bukittinggi
Indonesia GSK Investigational Site Denpasar
Indonesia GSK Investigational Site Depok Timur
Indonesia GSK Investigational Site Jakarta
Indonesia GSK Investigational Site Jakarta
Indonesia GSK Investigational Site Jakarta
Indonesia GSK Investigational Site Lampung Selatan
Indonesia GSK Investigational Site Makassar
Indonesia GSK Investigational Site Malang
Indonesia GSK Investigational Site Medan
Indonesia GSK Investigational Site Medan
Indonesia GSK Investigational Site Padang
Indonesia GSK Investigational Site Palembang
Indonesia GSK Investigational Site Pekanbaru
Indonesia GSK Investigational Site Pontianak
Indonesia GSK Investigational Site Pringsewu
Indonesia GSK Investigational Site Semarang
Indonesia GSK Investigational Site Surabaya
Indonesia GSK Investigational Site Surakarta
Indonesia GSK Investigational Site Yogyakarta
Israel GSK Investigational Site Afula
Israel GSK Investigational Site Ashkelon
Israel GSK Investigational Site Beer-Sheba
Israel GSK Investigational Site Hadera
Israel GSK Investigational Site Haifa
Israel GSK Investigational Site Haifa
Israel GSK Investigational Site Holon
Israel GSK Investigational Site Jerusalem
Israel GSK Investigational Site Kfar Saba
Israel GSK Investigational Site Rehovot
Israel GSK Investigational Site Tel Aviv
Israel GSK Investigational Site Tel Hashomer
Italy GSK Investigational Site Pordenone Friuli-Venezia-Giulia
Japan GSK Investigational Site Aichi
Japan GSK Investigational Site Aichi
Japan GSK Investigational Site Aichi
Japan GSK Investigational Site Fukuoka
Japan GSK Investigational Site Gifu
Japan GSK Investigational Site Hokkaido
Japan GSK Investigational Site Hokkaido
Japan GSK Investigational Site Hokkaido
Japan GSK Investigational Site Hyogo
Japan GSK Investigational Site Ibaraki
Japan GSK Investigational Site Kagawa
Japan GSK Investigational Site Kodaira
Japan GSK Investigational Site Kumamoto
Japan GSK Investigational Site Kyoto
Japan GSK Investigational Site Oita
Japan GSK Investigational Site Osaka
Japan GSK Investigational Site Osaka
Japan GSK Investigational Site Osaka
Japan GSK Investigational Site Shimane
Japan GSK Investigational Site Shimane
Japan GSK Investigational Site Tokyo
Japan GSK Investigational Site Tokyo
Japan GSK Investigational Site Tokyo
Korea, Republic of GSK Investigational Site Bucheon
Korea, Republic of GSK Investigational Site Bucheon-Si, Gyeonggi-Do
Korea, Republic of GSK Investigational Site Busan
Korea, Republic of GSK Investigational Site Cheonan
Korea, Republic of GSK Investigational Site Chonju-si
Korea, Republic of GSK Investigational Site Daegu
Korea, Republic of GSK Investigational Site Daejeon
Korea, Republic of GSK Investigational Site Daejeon
Korea, Republic of GSK Investigational Site Goyang-si
Korea, Republic of GSK Investigational Site Guri-si
Korea, Republic of GSK Investigational Site Gwangju
Korea, Republic of GSK Investigational Site Gyeonggi-do
Korea, Republic of GSK Investigational Site Incheon
Korea, Republic of GSK Investigational Site Incheon
Korea, Republic of GSK Investigational Site Kangwon
Korea, Republic of GSK Investigational Site Seongnam
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Seoul
Korea, Republic of GSK Investigational Site Suwon, Gyeonggi-do
Korea, Republic of GSK Investigational Site Uijeongbu, Gyeonggi-do
Korea, Republic of GSK Investigational Site Ulsan
Korea, Republic of GSK Investigational Site Wonju-si, Kanwon-do
Latvia GSK Investigational Site Balvi
Latvia GSK Investigational Site Daugavpils
Latvia GSK Investigational Site Daugavpils
Latvia GSK Investigational Site Jekabpils
Latvia GSK Investigational Site Jelgava
Latvia GSK Investigational Site Jurmala
Latvia GSK Investigational Site Kraslava
Latvia GSK Investigational Site Kuldiga
Latvia GSK Investigational Site Liepaja
Latvia GSK Investigational Site Ogre
Latvia GSK Investigational Site Riga
Latvia GSK Investigational Site Riga
Latvia GSK Investigational Site Riga
Latvia GSK Investigational Site Riga
Latvia GSK Investigational Site Riga
Latvia GSK Investigational Site Talsi
Latvia GSK Investigational Site Tukums
Latvia GSK Investigational Site Valmiera
Latvia GSK Investigational Site Ventspils
Macedonia, The Former Yugoslav Republic of GSK Investigational Site Bitola
Macedonia, The Former Yugoslav Republic of GSK Investigational Site Gostivar
Macedonia, The Former Yugoslav Republic of GSK Investigational Site Ohrid
Macedonia, The Former Yugoslav Republic of GSK Investigational Site Prilep
Macedonia, The Former Yugoslav Republic of GSK Investigational Site Shtip
Macedonia, The Former Yugoslav Republic of GSK Investigational Site Skopje
Macedonia, The Former Yugoslav Republic of GSK Investigational Site Strumica
Macedonia, The Former Yugoslav Republic of GSK Investigational Site Veles
Malaysia GSK Investigational Site Johor Bahru
Malaysia GSK Investigational Site Kuala Lumpur
Malaysia GSK Investigational Site Kuala Pilah
Malaysia GSK Investigational Site Kuching
Malaysia GSK Investigational Site Selangor
Malaysia GSK Investigational Site Sibu
Malaysia GSK Investigational Site Sungai Petani, Kedah
Malaysia GSK Investigational Site Taiping Perak
Mexico GSK Investigational Site Aguascalientes
Mexico GSK Investigational Site Chihuahua
Mexico GSK Investigational Site Chihuahua
Mexico GSK Investigational Site Cuautitlan Izcalli Estado De México
Mexico GSK Investigational Site Cuernavaca Morelos
Mexico GSK Investigational Site Guadalajara
Mexico GSK Investigational Site Guadalajara Jalisco
Mexico GSK Investigational Site Hermosillo Sonora
Mexico GSK Investigational Site Hidalgo
Mexico GSK Investigational Site Merida
Mexico GSK Investigational Site Mexico D.F
Mexico GSK Investigational Site México DF
Mexico GSK Investigational Site Monterrey
Mexico GSK Investigational Site Monterrey Nuevo León
Mexico GSK Investigational Site Monterrey Nuevo León
Mexico GSK Investigational Site Morelia Michoacán
Mexico GSK Investigational Site San luis Potosí
Mexico GSK Investigational Site Zapopan Jalisco
Netherlands GSK Investigational Site Alkmaar
Netherlands GSK Investigational Site Almelo
Netherlands GSK Investigational Site Ede Gld
Netherlands GSK Investigational Site Helmond
Netherlands GSK Investigational Site Zutphen
Philippines GSK Investigational Site Alabang, Muntinlupa City
Philippines GSK Investigational Site Caloocan
Philippines GSK Investigational Site Cavite
Philippines GSK Investigational Site Cebu City
Philippines GSK Investigational Site Dasmariñas, Cavite
Philippines GSK Investigational Site Davao
Philippines GSK Investigational Site Iloilo
Philippines GSK Investigational Site Iloilo City
Philippines GSK Investigational Site Jaro, Iloilo City
Philippines GSK Investigational Site Los Banos
Philippines GSK Investigational Site Manila
Philippines GSK Investigational Site Manila
Philippines GSK Investigational Site Marilao, Bulacan
Philippines GSK Investigational Site Pasay
Philippines GSK Investigational Site Pasig
Philippines GSK Investigational Site Quezon
Philippines GSK Investigational Site Quezon City
Philippines GSK Investigational Site Quezon City
Philippines GSK Investigational Site Quezon City
Philippines GSK Investigational Site Quezon City
Philippines GSK Investigational Site San Fernando, Pampanga
Poland GSK Investigational Site Bialystok
Poland GSK Investigational Site Bialystok
Poland GSK Investigational Site Bielsko-Biala
Poland GSK Investigational Site Bielsko-Biala
Poland GSK Investigational Site Bienkowka
Poland GSK Investigational Site Bydgoszcz
Poland GSK Investigational Site Bydgoszcz
Poland GSK Investigational Site Chelmza
Poland GSK Investigational Site Chodziez
Poland GSK Investigational Site Chorzow
Poland GSK Investigational Site Choszczno
Poland GSK Investigational Site Czestochowa
Poland GSK Investigational Site Dabrowa Gornicza
Poland GSK Investigational Site Dzialdowo
Poland GSK Investigational Site Elblag
Poland GSK Investigational Site Gdansk
Poland GSK Investigational Site Gdansk
Poland GSK Investigational Site Gdansk
Poland GSK Investigational Site Gdynia
Poland GSK Investigational Site Gorzow Wielkopolski
Poland GSK Investigational Site Grudziadz
Poland GSK Investigational Site Ilawa
Poland GSK Investigational Site Inowroclaw
Poland GSK Investigational Site Izabelin
Poland GSK Investigational Site Jelenia Gora
Poland GSK Investigational Site Karpacz
Poland GSK Investigational Site Katowice
Poland GSK Investigational Site Katowice
Poland GSK Investigational Site Kielce
Poland GSK Investigational Site Kielce
Poland GSK Investigational Site Kielce
Poland GSK Investigational Site Krakow
Poland GSK Investigational Site Krakow
Poland GSK Investigational Site Krakow
Poland GSK Investigational Site Krakow
Poland GSK Investigational Site Krakow
Poland GSK Investigational Site Krakow
Poland GSK Investigational Site Krotoszyn
Poland GSK Investigational Site Ksawerow
Poland GSK Investigational Site Kutno
Poland GSK Investigational Site Leczyca
Poland GSK Investigational Site Libiaz
Poland GSK Investigational Site Lodz
Poland GSK Investigational Site Lodz
Poland GSK Investigational Site Lodz
Poland GSK Investigational Site Lodz
Poland GSK Investigational Site Lodz
Poland GSK Investigational Site Lodz
Poland GSK Investigational Site Lodz
Poland GSK Investigational Site Lodz
Poland GSK Investigational Site Lodz
Poland GSK Investigational Site Lodz
Poland GSK Investigational Site Lublin
Poland GSK Investigational Site Lublin
Poland GSK Investigational Site Lublin
Poland GSK Investigational Site Olawa
Poland GSK Investigational Site Olsztyn
Poland GSK Investigational Site Ostrow Wilekopolski
Poland GSK Investigational Site Ostrowiec Swietokrzyski
Poland GSK Investigational Site Piaseczno
Poland GSK Investigational Site Pila
Poland GSK Investigational Site Plock
Poland GSK Investigational Site Police
Poland GSK Investigational Site Poznan
Poland GSK Investigational Site Poznan
Poland GSK Investigational Site Poznan
Poland GSK Investigational Site Poznan
Poland GSK Investigational Site Ruda Slaska
Poland GSK Investigational Site Rudka
Poland GSK Investigational Site Rzeszow
Poland GSK Investigational Site Skarzysko-Kamienna
Poland GSK Investigational Site Skierniewice
Poland GSK Investigational Site Slupsk
Poland GSK Investigational Site Sopot
Poland GSK Investigational Site Swidnik
Poland GSK Investigational Site Szczecin
Poland GSK Investigational Site Szczecin
Poland GSK Investigational Site Tarnow
Poland GSK Investigational Site Tczew
Poland GSK Investigational Site Torun
Poland GSK Investigational Site Warszawa
Poland GSK Investigational Site Warszawa
Poland GSK Investigational Site Warszawa
Poland GSK Investigational Site Warszawa
Poland GSK Investigational Site Wloclawek
Poland GSK Investigational Site Wloszczowa
Poland GSK Investigational Site Wodzislaw Slaski
Poland GSK Investigational Site Wroclaw
Poland GSK Investigational Site Wroclaw
Poland GSK Investigational Site Wroclaw
Poland GSK Investigational Site Wroclaw
Poland GSK Investigational Site Wroclaw
Poland GSK Investigational Site Zabrze
Poland GSK Investigational Site Zabrze
Poland GSK Investigational Site Zgierz
Romania GSK Investigational Site Arad
Romania GSK Investigational Site Bacau
Romania GSK Investigational Site Bragadiru
Romania GSK Investigational Site Brasov
Romania GSK Investigational Site Brasov
Romania GSK Investigational Site Bucarest
Romania GSK Investigational Site Bucharest
Romania GSK Investigational Site Bucharest
Romania GSK Investigational Site Bucharest
Romania GSK Investigational Site Bucharest
Romania GSK Investigational Site Bucuresti
Romania GSK Investigational Site Bucuresti
Romania GSK Investigational Site Bucuresti
Romania GSK Investigational Site Bucuresti
Romania GSK Investigational Site Bucuresti
Romania GSK Investigational Site Bucuresti
Romania GSK Investigational Site Bucuresti
Romania GSK Investigational Site Bucuresti
Romania GSK Investigational Site Bucuresti
Romania GSK Investigational Site Bucuresti
Romania GSK Investigational Site Bucuresti
Romania GSK Investigational Site Bucuresti
Romania GSK Investigational Site Campulung Muscel
Romania GSK Investigational Site Cluj-Napoca
Romania GSK Investigational Site Cluj-Napoca
Romania GSK Investigational Site Codlea
Romania GSK Investigational Site Constanta
Romania GSK Investigational Site Constanta
Romania GSK Investigational Site Deva
Romania GSK Investigational Site Iasi
Romania GSK Investigational Site Iasi
Romania GSK Investigational Site Iasi
Romania GSK Investigational Site Iasi
Romania GSK Investigational Site Pitesti
Romania GSK Investigational Site Pitesti
Romania GSK Investigational Site Ploiesti
Romania GSK Investigational Site Ramnicu Valcea
Romania GSK Investigational Site Suceava
Romania GSK Investigational Site Targu-Mures
Romania GSK Investigational Site Timisoara
Romania GSK Investigational Site Timisoara
Russian Federation GSK Investigational Site Arkhangelsk
Russian Federation GSK Investigational Site Arkhangelsk
Russian Federation GSK Investigational Site Barnaul
Russian Federation GSK Investigational Site Barnaul
Russian Federation GSK Investigational Site Chelyabinsk
Russian Federation GSK Investigational Site Chelyabinsk
Russian Federation GSK Investigational Site Chelyabinsk
Russian Federation GSK Investigational Site Ekaterinburg
Russian Federation GSK Investigational Site Ekaterinburg
Russian Federation GSK Investigational Site Ekaterinburg
Russian Federation GSK Investigational Site Gatchina
Russian Federation GSK Investigational Site Ivanovo
Russian Federation GSK Investigational Site Izhevsk
Russian Federation GSK Investigational Site Kaliningrad
Russian Federation GSK Investigational Site Kazan
Russian Federation GSK Investigational Site Kemerovo
Russian Federation GSK Investigational Site Kemerovo
Russian Federation GSK Investigational Site Kirov
Russian Federation GSK Investigational Site Krasnoyarsk
Russian Federation GSK Investigational Site Kursk
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Nizhniy Novgorod
Russian Federation GSK Investigational Site Novosibirsk
Russian Federation GSK Investigational Site Novosibirsk
Russian Federation GSK Investigational Site Novosibirsk
Russian Federation GSK Investigational Site Novosibirsk
Russian Federation GSK Investigational Site Novosibirsk
Russian Federation GSK Investigational Site Novosibirsk
Russian Federation GSK Investigational Site Novosibirsk
Russian Federation GSK Investigational Site Orenburg
Russian Federation GSK Investigational Site Orenburg
Russian Federation GSK Investigational Site Perm
Russian Federation GSK Investigational Site Perm
Russian Federation GSK Investigational Site Perm
Russian Federation GSK Investigational Site Pskov
Russian Federation GSK Investigational Site Rostov-on-Don
Russian Federation GSK Investigational Site Ryazan
Russian Federation GSK Investigational Site Ryazan
Russian Federation GSK Investigational Site Ryazan
Russian Federation GSK Investigational Site Saint Petersburg
Russian Federation GSK Investigational Site Saint Petersburg
Russian Federation GSK Investigational Site Saint Petersburg
Russian Federation GSK Investigational Site Saint Petersburg
Russian Federation GSK Investigational Site Saint Petersburg
Russian Federation GSK Investigational Site Saint Petersburg
Russian Federation GSK Investigational Site Saint-Petersburg
Russian Federation GSK Investigational Site Saint-Petersburg
Russian Federation GSK Investigational Site Saint-Petersburg
Russian Federation GSK Investigational Site Saint-Petersburg
Russian Federation GSK Investigational Site Saint-Petersburg
Russian Federation GSK Investigational Site Saint-Petersburg
Russian Federation GSK Investigational Site Saratov
Russian Federation GSK Investigational Site Saratov
Russian Federation GSK Investigational Site Saratov
Russian Federation GSK Investigational Site Saratov
Russian Federation GSK Investigational Site Saratov
Russian Federation GSK Investigational Site Sestroretsk
Russian Federation GSK Investigational Site Smolensk
Russian Federation GSK Investigational Site Smolensk
Russian Federation GSK Investigational Site St Petersburg
Russian Federation GSK Investigational Site St Petersburg
Russian Federation GSK Investigational Site St'Petersburg
Russian Federation GSK Investigational Site St-Petersburg
Russian Federation GSK Investigational Site St-Petersburg
Russian Federation GSK Investigational Site St-Petersburg
Russian Federation GSK Investigational Site St. Petersburg
Russian Federation GSK Investigational Site St. Petersburg
Russian Federation GSK Investigational Site St. Petersburg
Russian Federation GSK Investigational Site St. Petersburg
Russian Federation GSK Investigational Site St.?etersburg
Russian Federation GSK Investigational Site St.Petersburg
Russian Federation GSK Investigational Site St.Petersburg
Russian Federation GSK Investigational Site Tomsk
Russian Federation GSK Investigational Site Tomsk
Russian Federation GSK Investigational Site Tomsk
Russian Federation GSK Investigational Site Tomsk
Russian Federation GSK Investigational Site Tver
Russian Federation GSK Investigational Site Ufa
Russian Federation GSK Investigational Site Ulyanovsk
Russian Federation GSK Investigational Site Voronezh
Russian Federation GSK Investigational Site Voronezh
Russian Federation GSK Investigational Site Vsevolzhsk
Russian Federation GSK Investigational Site Yaroslavl
Russian Federation GSK Investigational Site Yaroslavl
Russian Federation GSK Investigational Site Yaroslavl
Russian Federation GSK Investigational Site Yaroslavl
Russian Federation GSK Investigational Site Yaroslavl
Serbia GSK Investigational Site Belgrade
Serbia GSK Investigational Site Belgrade
Serbia GSK Investigational Site Cacak
Serbia GSK Investigational Site Kragujevac
Serbia GSK Investigational Site Nis
Serbia GSK Investigational Site Sombor
Serbia GSK Investigational Site Sremska Kamenica
Serbia GSK Investigational Site Valjevo
Slovakia GSK Investigational Site Bratislava
Slovakia GSK Investigational Site Bratislava
Slovakia GSK Investigational Site Bratislava
Slovakia GSK Investigational Site Bratislava
Slovakia GSK Investigational Site Kosice
Slovakia GSK Investigational Site Kralovsky Chlmec
Slovakia GSK Investigational Site Nove Zamky
Slovakia GSK Investigational Site Presov
Slovakia GSK Investigational Site Presov
Slovakia GSK Investigational Site Spisska Nova Ves
Slovakia GSK Investigational Site Sturovo
Slovakia GSK Investigational Site Trnava
Slovakia GSK Investigational Site Vrable
South Africa GSK Investigational Site Benoni Gauteng
South Africa GSK Investigational Site Benoni
South Africa GSK Investigational Site Bloemfontein
South Africa GSK Investigational Site Boksburg Gauteng
South Africa GSK Investigational Site Cape Town
South Africa GSK Investigational Site Cape Town
South Africa GSK Investigational Site Cape Town
South Africa GSK Investigational Site Cape Town
South Africa GSK Investigational Site Cape Town
South Africa GSK Investigational Site CapeTown
South Africa GSK Investigational Site Dundee KwaZulu- Natal
South Africa GSK Investigational Site Durban
South Africa GSK Investigational Site Durban
South Africa GSK Investigational Site Gatesville
South Africa GSK Investigational Site Johannesburg
South Africa GSK Investigational Site Korsten
South Africa GSK Investigational Site Lynnwood Ridge
South Africa GSK Investigational Site Meyerspark Gauteng
South Africa GSK Investigational Site Middelburg Mpumalanga
South Africa GSK Investigational Site Morningside Gauteng
South Africa GSK Investigational Site Mowbray
South Africa GSK Investigational Site Paarl
South Africa GSK Investigational Site Panorama
South Africa GSK Investigational Site Potchefstroom
South Africa GSK Investigational Site Pretoria
South Africa GSK Investigational Site Pretoria
South Africa GSK Investigational Site Pretoria Gauteng
South Africa GSK Investigational Site Pretoria Gauteng
South Africa GSK Investigational Site Pretoria Gauteng
South Africa GSK Investigational Site Pretoria Gauteng
South Africa GSK Investigational Site Roodepoort
South Africa GSK Investigational Site Rooihuiskraal
South Africa GSK Investigational Site Somerset West
South Africa GSK Investigational Site Thaba Tshwane Gauteng
South Africa GSK Investigational Site Thabazimbi
South Africa GSK Investigational Site Tygerberg
South Africa GSK Investigational Site Voorspoed
Spain GSK Investigational Site Badalona
Spain GSK Investigational Site Barcelona
Spain GSK Investigational Site Barcelona
Spain GSK Investigational Site Barcelona
Spain GSK Investigational Site Barcelona
Spain GSK Investigational Site Benidorm
Spain GSK Investigational Site Canet De Mar - Barcelona
Spain GSK Investigational Site Galdakano
Spain GSK Investigational Site Illescas-Toledo
Spain GSK Investigational Site Jerez de la Frontera
Spain GSK Investigational Site L'Hospitalet de Llobregat
Spain GSK Investigational Site Madrid
Spain GSK Investigational Site Madrid
Spain GSK Investigational Site Mataró
Spain GSK Investigational Site Oviedo
Spain GSK Investigational Site Palma de Mallorca
Spain GSK Investigational Site Pamplona
Spain GSK Investigational Site Pozuelo De Alarcón/Madrid
Spain GSK Investigational Site Sabadell (Barcelona)
Spain GSK Investigational Site Sagunto/Valencia
Spain GSK Investigational Site Sant Boi de Llobregat
Spain GSK Investigational Site Santa Coloma de Gramenet
Spain GSK Investigational Site Santiago de Compostela
Spain GSK Investigational Site Torrelavega
Spain GSK Investigational Site Valencia
Spain GSK Investigational Site Vic (Barcelona)
Taiwan GSK Investigational Site Changhua
Taiwan GSK Investigational Site Chia-Yi
Taiwan GSK Investigational Site Kaohsiung
Taiwan GSK Investigational Site Kaohsiung Hsien
Taiwan GSK Investigational Site Keelung
Taiwan GSK Investigational Site LinKou
Taiwan GSK Investigational Site Taichung
Taiwan GSK Investigational Site Taichung
Taiwan GSK Investigational Site Taichung
Taiwan GSK Investigational Site Taichung
Taiwan GSK Investigational Site Taichung
Taiwan GSK Investigational Site Tainan
Taiwan GSK Investigational Site Taipei
Taiwan GSK Investigational Site Taipei
Taiwan GSK Investigational Site Taipei
Taiwan GSK Investigational Site Taipei
Taiwan GSK Investigational Site Taipei
Taiwan GSK Investigational Site Yung Kang City
Thailand GSK Investigational Site Bangkok
Thailand GSK Investigational Site Bangkok
Thailand GSK Investigational Site Bangkok
Thailand GSK Investigational Site Bangkok
Thailand GSK Investigational Site Bangkok
Thailand GSK Investigational Site Chiangmai
Thailand GSK Investigational Site Chiangrai
Thailand GSK Investigational Site Khon Kaen
Thailand GSK Investigational Site Mae Rim, Chiang Mai
* Note: There are 1621 locations in all - only the first 1000 are shown.

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Vietnam,  Argentina,  Australia,  Austria,  Belarus,  Belgium,  Bosnia and Herzegovina,  Bulgaria,  Canada,  Chile,  China,  Colombia,  Croatia,  Czechia,  France,  Georgia,  Germany,  Greece,  Hungary,  India,  Indonesia,  Israel,  Italy,  Japan,  Korea, Republic of,  Latvia,  Macedonia, The Former Yugoslav Republic of,  Malaysia,  Mexico,  Netherlands,  Philippines,  Poland,  Romania,  Russian Federation,  Serbia,  Slovakia,  South Africa,  Spain,  Taiwan,  Thailand,  Turkey,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date Death from any cause: which occurred from the day of starting IP until the Commone End Date (CED). Common End Date (CED) is the study end date that was pre determined where approximately 1000 deaths would have occurred in the Intent-toTreat Efficacy (ITT-E) Population. Only deaths which occurred on or before the CED were used for the primary analysis. Those who had not died by CED, but who were known to be alive on or after the CED, were censored at the CED. Cox Proportional Hazards (PH) Model was adjusted for age, and gender, including all 4 arms. A hazard ratio of less than 1 indicates a lower death rate versus placebo or other arm. ITT-E Population consisted of all participants in the Safety Population (i.e. randomized to IP and who received at least one dose of IP), with the exception of those recruited at sites that were closed. From the date of randomization until date of death due to any cause (average of 2 study years)
Secondary Decline in Forced Expiratory Volume in 1 Second (FEV1) FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The effect of treatment on decline of post bronchodilator FEV1 recorded during the treatment period was analyzed using a particular form of a mixed effect model - a random coefficients model. FEV1 was fitted as the response variable with treatment group, age, gender, baseline FEV1 and time on treatment as fixed effects. Time on treatment was treated as a continuous variable. This model allowed for an initial increase in FEV1, but then tested the difference in slopes from the first post-baseline measurement which was at 3 months. A negative slope indicates a decline. A positive treatment difference indicates a slower rate of decline vs Placebo or Component. Only participants with at least one on-treatment post-bronchodilator FEV1 measurement were analyzed. From start date of IP until IP stop date + 1 (assessed up to 4 years)
Secondary Number of Participants With First On-treatment Cardiovascular (CV) Composite Events Occured on or Before Common End Date On-treatment CV composite event is comprised of the first event that is adjudicated as on-treatment CV death, myocardial infarction, stroke, unstable angina, or transient ischemic attack experienced by a participant. The events that occurred no more than 7 days after the participants last dose of IP are considered as on-treatment adverse events. Common end date is the study end date where approximately 1000 deaths would have occurred in the ITT-E Population. Cox PH Model was used to assess time to first on-treatment CV composite event. Cox PH Model was adjusted for age, gender and indicators of ischemic and vascular disease, including all four treatment arms. A hazard ratio less than 1 indicates a lower risk of a first CV event rate versus placebo or any arm. From the start of IP to first on treatment CV event till 7 days after the last dose of IP (average of 2 study years)
See also
  Status Clinical Trial Phase
Completed NCT05043428 - The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD N/A
Completed NCT00528996 - An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler. Phase 2
Completed NCT03740373 - A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate Phase 1
Completed NCT05402020 - Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
Completed NCT05393245 - Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
Completed NCT04011735 - Re-usable Respimat® Soft MistTM Inhaler Study
Enrolling by invitation NCT03075709 - The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
Completed NCT03764163 - Image and Model Based Analysis of Lung Disease Early Phase 1
Completed NCT00515268 - Endotoxin Challenge Study For Healthy Men and Women Phase 1
Completed NCT04085302 - TARA Working Prototype Engagement Evaluation: Feasibility Study N/A
Completed NCT03691324 - Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study N/A
Completed NCT02236611 - A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT00153075 - Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT01017952 - A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT01009463 - A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT04882124 - Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD Phase 2
Completed NCT02853123 - Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients Phase 4
Completed NCT02619357 - Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma Phase 1
Recruiting NCT05858463 - High Intensity Interval Training and Muscle Adaptations During PR N/A
Not yet recruiting NCT05032898 - Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II